With the support and help of the Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins, SanuLife Inc. launched its ROVIDIUM
products on August 13th, at the anniversary celebration of the
company held at the Johns Hopkins University School of Medicine in
Baltimore, which was witnessed by Dr. Zhang, Founder of SanuLife,
together with his partner Mr. Chunshui Liu, and many other
distinguished guests.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180815005447/en/
Dr. Chunyu Zhang, the founder, Mr.
Chunshui Liu, the partner, and the guests take a group photo
(Photo: Business Wire)
Dr. Bert Vogelstein, Laureate of 2013 Breakthrough Prize in Life
Sciences, and Mr. Farzam Kamalabadi, CEO of the US Future Trends
International Group sent their congratulatory messages. The event
was also graced by Dr. Hans Spiegel, the Germany-and-US-trained MD,
PhD physician-scientist with over 30 years of experience in the
patient care, clinical and basic research, as well as many friends
and colleagues of Dr. Zhang in Washington DC and on Johns Hopkins
Hospital campus.
ROVIDIUM, the result of Dr. Zhang’s 20-year anti-cancer and
anti-aging research, promises safe, effective, and technically
reliable production. By selecting high-purity anti-cancer small
molecules from natural ingredients, the carefully formulated
product enables continuous and efficient recovery of tumor
suppressor gene expression that induces apoptosis of cancer cells.
It can also slow down aging, reduce canceration and prolong healthy
lifespan by enhancing the internal protection mechanism,
down-regulating growth signal stimulation and inhibiting chronic
inflammatory response in normal cells.
A Breakthrough after 20-year Research
During the launch event, Dr. Zhang said, “It is truly remarkable
to launch ROVIDIUM at the first anniversary of SanuLife in the
Albert Owens Auditorium at the Sidney Kimmel Comprehensive Cancer
Center of Johns Hopkins University School of Medicine. For this,
I’d like to appreciate the center director William Nelson’s help,
Hopkins AV support and custodial services, and express my heartfelt
gratitude to the guests for your participation. ROVIDIUM is a
result of many years of research and the very first product of
SanuLife. I hope it will create new directions and impetus for
cancer research, and that customers will find it useful and
effective.”
“For researchers, nothing can be more exciting than launching
new products. It spurs me and my team to conduct more innovative
research and accelerate commercialization of achievements, so as to
make more contribution to human health,” Zhang added.
As the principal investigator of the Lung Cancer and Aging
Project at Sidney Kimmel Comprehensive Cancer Center, Dr. Zhang has
been engaged in cancer research for nearly 20 years. He has
produced a host of internationally leading research results in such
fields as “Clock of Life” telomere and telomerase, nuclear encoded
mitochondrial longevity mutant protein, aging-associated chronic
inflammation, obesity and cancer biomarker FAT10, immunoregulation
factor gene expression and tissue localization, gene expression
change during lung cancer progression, chemotherapy resistance and
prognosis survival. His findings have been published in Cell, PNAS,
Genomics, Cancer Research, Molecular Cancer Therapeutics and
Nature, etc.
SanuLife’s partner Chunshui Liu said, “As our very first
product, ROVIDIUM combines the most advanced technology of SanuLife
and the 20-year research results of Dr. Zhang. It is a breakthrough
in cancer prevention and anti-aging fields. ROVIDIUM will be a new
starting point for SanuLife committed to the big health industry.
SanuLife will focus on research and development of science-based
health management, biomedicine and health-care products. With
optimal resources and most forward-looking technology at SanuLife,
we will provide consumers with one-stop, customized and intelligent
health-care services.”
Before meeting consumers, ROVIDIUM had been widely reported by
media including the Associated Press, one of the four major
international news agencies, and Yahoo, the mainstream US financial
media.
A Single Solution to Dual Problems
The anti-cancer and anti-aging ROVIDIUM gives play to the
synergy between the tumor suppressor genes RhoB and p21 and the
longevity transcriptional factor Nrf2, which drives expression of
endogenous antioxidant, anti-inflammatory and anti-fibrotic genes.
The product restores RhoB expression, which is continuously
down-regulated by epigenetics during pulmonary aging, skeletal
muscle decline, and tumorigenesis, and activates Nrf2 through p21
to stabilize the genome and protect cells from carcinogenesis,
which aims to help delay aging, prevent cancer and increase
longevity.
The ROVIDIUM ingredients and raw materials are selected in a
most strict manner. The core ingredients are rice germ and rice
bran extract Ceramide, turmeric extract Curcumin and green tea
extract EGCG, with raw materials meticulously selected from
well-known suppliers of Japan, Germany, China and the US. The
ingredients are evaluated by the US FDA as “Generally Recognized as
Safe” (GRAS). Purified by high-tech and micro-encapsulated,
ROVIDIUM features excellent purity, sustained-release stability and
bioavailability. It’s produced and packaged by a selected
Californian partner in accordance with the cGMP standard and
above.
As a responsible scientist, Dr. Zhang has entrusted a third
party to conduct verification experiments on ROVIDIUM products.
Preliminary results indicated that ROVIDIUM has tackled the
bottleneck of low solubility of core ingredients, which proves to
be highly water soluble. Validation experiments on A549 cells of
non-small cell lung cancer prevalent in the US and China showed
that ROVIDIUM core and luxury versions can dose-dependently induce
the tumor suppressor gene RhoB and efficiently inhibit the Akt/mTOR
signaling pathway which is critical in the process of canceration
and aging, thus significantly inhibiting proliferation, metastasis
and survival of A549 cells. Moreover, further validation
experiments on Panc02 cells of the aggressive pancreatic cancer
showed that ROVIDIUM killed malignant Panc02 cells even more than
relatively well-differentiated A549 cells.
As a dietary supplement, ROVIDIUM is not subject to preclinical
or clinical trial requirements. Still SanuLife signed a cooperative
agreement with HD Biosciences Inc. to carry out preclinical animal
experiments for ROVIDIUM. Preparation is now under way for a first
trial on the Panc02 syngeneic tumor models.
Meanwhile, SanuLife has opened its official flagship store on
the cross-border e-commerce platform XIJI.COM. Both core and luxury
versions of ROVIDIUM are now available online.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180815005447/en/
SanuLife IncAngel Zhang, +1 443 251 6397info@sanulife.com